Cargando…
P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642058/ http://dx.doi.org/10.1097/01.HS9.0000890996.84518.13 |
| _version_ | 1784826221966655488 |
|---|---|
| author | Driessen, Julia De Wit, Fer Herrera, Alex F. Zinzani, Pier Luigi Lacasce, Ann S. Cole, Peter D. Moskowitz, Craig H. Sanz, Ramón. García Fuchs, Michael Müller, Horst Borchmann, Peter Santoro, Armando Schöder, Heiko Zijlstra, Josée. M. Hutten, Barbara A. Moskowitz, Alison J. Kersten, Marie José |
| author_facet | Driessen, Julia De Wit, Fer Herrera, Alex F. Zinzani, Pier Luigi Lacasce, Ann S. Cole, Peter D. Moskowitz, Craig H. Sanz, Ramón. García Fuchs, Michael Müller, Horst Borchmann, Peter Santoro, Armando Schöder, Heiko Zijlstra, Josée. M. Hutten, Barbara A. Moskowitz, Alison J. Kersten, Marie José |
| author_sort | Driessen, Julia |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9642058 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96420582022-11-14 P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data Driessen, Julia De Wit, Fer Herrera, Alex F. Zinzani, Pier Luigi Lacasce, Ann S. Cole, Peter D. Moskowitz, Craig H. Sanz, Ramón. García Fuchs, Michael Müller, Horst Borchmann, Peter Santoro, Armando Schöder, Heiko Zijlstra, Josée. M. Hutten, Barbara A. Moskowitz, Alison J. Kersten, Marie José Hemasphere Relapsed/Refractory Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9642058/ http://dx.doi.org/10.1097/01.HS9.0000890996.84518.13 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Relapsed/Refractory Driessen, Julia De Wit, Fer Herrera, Alex F. Zinzani, Pier Luigi Lacasce, Ann S. Cole, Peter D. Moskowitz, Craig H. Sanz, Ramón. García Fuchs, Michael Müller, Horst Borchmann, Peter Santoro, Armando Schöder, Heiko Zijlstra, Josée. M. Hutten, Barbara A. Moskowitz, Alison J. Kersten, Marie José P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data |
| title | P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data |
| title_full | P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data |
| title_fullStr | P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data |
| title_full_unstemmed | P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data |
| title_short | P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data |
| title_sort | p107: effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed/refractory hodgkin lymphoma: a large multi-trial analysis based on individual patient data |
| topic | Relapsed/Refractory |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642058/ http://dx.doi.org/10.1097/01.HS9.0000890996.84518.13 |
| work_keys_str_mv | AT driessenjulia p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT dewitfer p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT herreraalexf p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT zinzanipierluigi p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT lacasceanns p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT colepeterd p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT moskowitzcraigh p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT sanzramongarcia p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT fuchsmichael p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT mullerhorst p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT borchmannpeter p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT santoroarmando p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT schoderheiko p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT zijlstrajoseem p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT huttenbarbaraa p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT moskowitzalisonj p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata AT kerstenmariejose p107effectofbrentuximabvedotinadditiontochemotherapyandprognosticfactorsinpatientswithrelapsedrefractoryhodgkinlymphomaalargemultitrialanalysisbasedonindividualpatientdata |